Stroke prevention: Learning from the master (and COMMANDER)

Sci Transl Med. 2018 Sep 19;10(459):eaav0340. doi: 10.1126/scitranslmed.aav0340.

Abstract

Adding rivaroxaban to standard therapy in patients with heart failure and no atrial fibrillation did not show any beneficial effect on death risk.

Publication types

  • Comment

MeSH terms

  • Atrial Fibrillation*
  • Factor Xa Inhibitors
  • Heart Failure*
  • Humans
  • Rivaroxaban
  • Stroke*

Substances

  • Factor Xa Inhibitors
  • Rivaroxaban